Liposomal bupivacaine in thoracic surgery: a comprehensive review of current evidence and clinical implications

Liuchun Huang, Jing He, Jiaping Wei, Xiuming Huang, Xianglan Chen, Qi Yang, Yonglong Zhong · 2026

Read Liposomal bupivacaine in thoracic surgery: a comprehensive review of current evidence and clinical implications by Liuchun Huang, Jing He, Jiaping Wei, Xiuming Huang, Xianglan Chen, Qi Yang, Yonglong Zhong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13613016.txt.

Description

Liuchun Huang and co-authors reviewed a long-acting pain drug for chest surgery, in a 2026 paper. The drug, liposomal bupivacaine, packs a classic numbing agent into tiny fat bubbles that leak it slowly. One shot can ease pain for three to four days. Chest surgery hurts badly, and cutting opioid use matters for recovery. The team weighed pain scores, opioid use, hospital stays, and safety across the published trials.

Pooled trials do show lower pain and less opioid use with the drug. The catch is size: the opioid saved in the first day is far below what doctors count as a real gain. Gains held up better for some nerve block types than others, and the drug shone most inside full recovery programs. Early signs hint it may cut long-term pain. The authors want bigger, longer trials before firm claims.

Catalog record

CREATORLiuchun Huang, Jing He, Jiaping Wei, Xiuming Huang, Xianglan Chen, Qi Yang, Yonglong Zhong
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13613016

Browse the full library · About the Tower of Babel